Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Get Free Report)'s share price dropped 9% on Friday . The company traded as low as $8.41 and last traded at $8.16. Approximately 892,665 shares traded hands during trading, a decline of 55% from the average daily volume of 1,974,700 shares. The stock had previously closed at $8.97.
MNMD has been the topic of a number of research reports. Leerink Partnrs upgraded Mind Medicine (MindMed) to a "strong-buy" rating in a research report on Friday, October 11th. Oppenheimer reiterated an "outperform" rating and set a $20.00 price target on shares of Mind Medicine (MindMed) in a research report on Tuesday, December 17th. Leerink Partners initiated coverage on Mind Medicine (MindMed) in a research report on Monday, October 14th. They set an "outperform" rating and a $20.00 price target on the stock. HC Wainwright reiterated a "buy" rating and set a $55.00 price target on shares of Mind Medicine (MindMed) in a research report on Friday, January 31st. Finally, Evercore ISI assumed coverage on Mind Medicine (MindMed) in a research report on Tuesday, January 28th. They issued an "outperform" rating and a $23.00 target price on the stock. Ten equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $26.33.
View Our Latest Stock Report on Mind Medicine (MindMed)
The firm has a market capitalization of $605.71 million, a price-to-earnings ratio of -3.65 and a beta of 2.59. The business has a 50-day moving average of $7.29 and a two-hundred day moving average of $6.94. The company has a quick ratio of 9.00, a current ratio of 9.00 and a debt-to-equity ratio of 0.09.
Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.02. During the same period last year, the company earned ($0.53) EPS. Research analysts predict that Mind Medicine will post -1.35 EPS for the current fiscal year.
In other news, CEO Robert Barrow sold 19,106 shares of the business's stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $7.43, for a total value of $141,957.58. Following the completion of the transaction, the chief executive officer now owns 526,666 shares of the company's stock, valued at $3,913,128.38. The trade was a 3.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Dan Karlin sold 6,643 shares of the company's stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $7.43, for a total transaction of $49,357.49. Following the completion of the transaction, the insider now directly owns 338,013 shares of the company's stock, valued at approximately $2,511,436.59. The trade was a 1.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,022 shares of company stock worth $208,203 in the last quarter. Insiders own 2.26% of the company's stock.
A number of large investors have recently modified their holdings of MNMD. Geode Capital Management LLC boosted its stake in shares of Mind Medicine (MindMed) by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,677,702 shares of the company's stock worth $9,548,000 after buying an additional 162,933 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Mind Medicine (MindMed) by 142.6% in the 3rd quarter. Wellington Management Group LLP now owns 185,722 shares of the company's stock valued at $1,057,000 after purchasing an additional 109,152 shares during the period. Barclays PLC raised its holdings in shares of Mind Medicine (MindMed) by 203.6% in the 3rd quarter. Barclays PLC now owns 136,098 shares of the company's stock valued at $775,000 after purchasing an additional 91,271 shares during the period. XTX Topco Ltd bought a new stake in shares of Mind Medicine (MindMed) in the 3rd quarter valued at about $337,000. Finally, Oppenheimer & Co. Inc. bought a new stake in shares of Mind Medicine (MindMed) in the 3rd quarter valued at about $298,000. 27.91% of the stock is currently owned by institutional investors and hedge funds.
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Mind Medicine (MindMed), you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mind Medicine (MindMed) wasn't on the list.
While Mind Medicine (MindMed) currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.